Flaig: It has been a remarkable 10 years for bladder cancer. If you think back to 10 or 15 years ago, we had no new ...
Targeted MAPK pathway inhibition with atebimetinib contrasts with nonselective cytotoxic chemotherapy and is paired with a dose-schedule modification intended to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results